John Garvey, associé chez Foley Private Equity & Venture Capital, a animé cette session avec les intervenants Josh Hamermesh de Molecular Insight Pharmaceuticals, Inc. et Matt Karlyn de Foley. Ils ont abordé les thèmes suivants : l'acquisition de licences technologiques, en particulier comment identifier les opportunités de profit potentielles ; l'approche des partenaires commerciaux potentiels, la diligence raisonnable avant la transaction ; la négociation avec le concédant de licence ; et l'intégration de la technologie sous licence dans les activités commerciales de l'entreprise.
Perspectives connexes
December 24, 2025
Health Care Law Today
Gender-Affirming Care: Multi‑State Lawsuit Challenges HHS Declaration
As previously discussed in Foley’s healthcarelawtoday, on December 18, 2025, the U.S. Department of Health & Human Services (HHS) held a press conference focused on what it defined as “sex rejection procedures” (SRPs), also known as gender-affirming care (GAC) for minors, and outlined next steps.
December 23, 2025
Energy Current
FERC Opens New Paths for Co-Located Loads in PJM: What Data Center and Power Generation Developers Need to Know
Key Takeaways FERC has ordered PJM to overhaul its tariff framework for co-located generation and large loads, finding existing rules…
December 23, 2025
Foley Viewpoints
The Rush to Exit: PE Firms Pick Up the Pace in 2025
Key Points: PE firms are moving to sell portfolio companies on an accelerated timeline in 2025 after years of much longer hold…